| 国产安吖啶治疗急性白血病Ⅱ期临床试用 |
| |
| 引用本文： | 江滨,王德炳,付剑峰,单福香,李永敢,陆道培. 国产安吖啶治疗急性白血病Ⅱ期临床试用[J]. 北京大学学报(医学版), 1993, 0(5) |
| |
| 作者姓名： | 江滨 王德炳 付剑峰 单福香 李永敢 陆道培 |
| |
| 作者单位： | 北京医科大学血液病研究所(江滨，王德炳，付剑峰，单福香，李永敢)，北京医科大学血液病研究所(陆道培) |
| |
| 摘 要： | 应用国产安吖啶对11例急性白血病进行诱导缓解化疗,初治6例,复治5例。4例达完全缓解(CR),CR率为36.4％。其中初治者为33.3％(2/6),复治者为40％(2/5)。总有效率45.5％。该药的剂量限制性毒性反应为骨髓抑制,部分病例有肝功能损害。
|
| 关 键 词： | 安吖啶 急性白血病 缓解率 |
PHASE II TRIAL OF AMSACRINE IN PATIENTS WITH ACUTE LEUKEMIA |
| |
| Abstract: | Eleven patients with acute leukemia received remission induction chemotherapy with amsacrine (m-AMSA). Six patients were previously untreated, 2 were in relapse, and 3 were refractory. Four pati-ents (36.4%) reached complete remission (CR). Total response rate is 45.5%. Subset analysis showedthe following CR rates: previously untreated 33.3%, relapsed and primary refractory 40%. The dose-limiting toxicity of m-AMSA is myelosuppression. Another side effect is impairment of hepatic func-tion. |
| |
| Keywords: | m-AMSA Acute leukemia Remission rate |
| 本文献已被 CNKI 等数据库收录！ |
|
